Literature DB >> 21187462

Experimental model and immunohistochemical comparison of U87 human glioblastoma cell xenografts on the chicken chorioallantoic membrane and in rat brains.

Tadej Strojnik1, Rajko Kavalar, Tara A Barone, Robert J Plunkett.   

Abstract

BACKGROUND: To study the neuropathology and selected tumour markers of malignant gliomas, an animal glioma model was developed using the implantation of U87 human glioblastoma cells into chick chorioallantoic membrane. The immunohistochemical characteristics were studied and compared with an orthotopic rodent model.
MATERIALS AND METHODS: The U87 cell suspension was inoculated onto the chick chorioallantoic membrane on embryonic day seven and into the brain of nude rats. Brain tumour sections were examined for various known tumour markers by routine haematoxylin and eosin staining and immunohistochemical analyses.
RESULTS: The immunohistochemical analyses showed that S100 protein, glial fibrillary acidic protein and synaptophysin expressions, initially present in tissue culture, were lost in both models. Persistent kallikrein, CD68 and vimentin expressions in U87 cells, as well as in both animal tumour models, were detected. The percentage of p53-positive nuclei, which was higher in the tumours grown on the chick chorioallantoic membrane than in rats, did not correlate with the Ki-67 labelling index. Strong cathepsin expression was maintained from the cell culture to both tumour models. CD3-positive cells and numerous leukocytes, but no CD20-positive cells were detected in any of the animal samples, indicating the immunological response of the host to be primarily cellular. Stronger immune reaction for vascular endothelial growth factor in rats correlated with an observed increase in vascular proliferation in these tumours.
CONCLUSION: A simple, fast-growing, cheap and well-defined chick chorioallantoic membrane model of glioma was established, providing a basis for further experimental studies of genetic and protein expression during human glioma tumourigenesis. This model may possibly replace some rodent models for selective studies.

Entities:  

Mesh:

Year:  2010        PMID: 21187462

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  The Chicken Embryo Chorioallantoic Membrane as an In Vivo Model for Photodynamic Therapy.

Authors:  Jaroslava Joniová; Georges Wagnières
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies.

Authors:  Pei-Yu Chu; Angele Pei-Fern Koh; Jane Antony; Ruby Yun-Ju Huang
Journal:  Cells Tissues Organs       Date:  2021-03-29       Impact factor: 2.208

3.  Using the Chicken Chorioallantoic Membrane In Vivo Model to Study Gynecological and Urological Cancers.

Authors:  Allison C Sharrow; Moe Ishihara; Junhui Hu; Il Hyun Kim; Lily Wu
Journal:  J Vis Exp       Date:  2020-01-28       Impact factor: 1.355

4.  Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery.

Authors:  Desmond B S Pink; Wendy Schulte; Missag H Parseghian; Andries Zijlstra; John D Lewis
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 5.  Application of the chick embryo chorioallantoic membrane in neurosurgery disease.

Authors:  Yong-Jie Yuan; Kan Xu; Wei Wu; Qi Luo; Jin-Lu Yu
Journal:  Int J Med Sci       Date:  2014-10-27       Impact factor: 3.738

6.  Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors.

Authors:  Natássia C R Corrêa; Hellen Kuasne; Jerusa A Q A Faria; Ciça C S Seixas; Iria G D Santos; Francine B Abreu; Suely Nonogaki; Rafael M Rocha; Gerluza Aparecida Borges Silva; Helenice Gobbi; Silvia R Rogatto; Alfredo M Goes; Dawidson A Gomes
Journal:  Oncol Rep       Date:  2013-02-12       Impact factor: 3.906

7.  Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis.

Authors:  Noor A Lokman; Alison S F Elder; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2012-08-10       Impact factor: 6.208

8.  Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.

Authors:  Martyn A Sharpe; Andrew D Livingston; Taylor L Gist; Pardip Ghosh; Junyan Han; David S Baskin
Journal:  EBioMedicine       Date:  2015-08-08       Impact factor: 8.143

9.  Assessment of tumor growth factor-β1 neutralizing antibody in the treatment of allergic rhinitis and asthma.

Authors:  Yan Wei; Zhili Zhang; Feng Wang; Shuihong Zhou
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

10.  Assessment of the proliferation status of glioblastoma cell and tumour tissue after nanoplatinum treatment.

Authors:  Marta Kutwin; Ewa Sawosz; Slawomir Jaworski; Mateusz Wierzbicki; Barbara Strojny; Marta Grodzik; André Chwalibog
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.